SCHEMBL321863

SCHEMBL321863

COc1c(C)c(C(=O)c2ccc3[nH]c(=O)n(O)c(=O)c3c2)n2ccccc12

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CA12 O43570 10/20 0.41
CA9 Q16790 10/20 0.41
FEN1 P39748 3/20 0.40
ERCC1 P07992 2/20 0.40
ERCC4 Q92889 2/20 0.40
DNASE1 P24855 1/20 0.40
RNASEH1 O60930 1/20 0.40
ERCC5 P28715 1/20 0.40
HTT P42858 1/20 0.38
ALDH1A1 P00352 4/20 0.38
MAPT P10636 2/20 0.38
LMNA P02545 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14916577 0.90 BRD4 (0.40) HTTALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL321471 0.90 ALDH1A1 (0.39) HTTALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL14917190 0.86 NPC1 (0.40) HTTALDH1A1MAPTSMN1; SMN2KMT2A
SCHEMBL14916426 0.86 MAPT (0.39) HTTALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL17004133 0.86 HTT (0.37) HTTALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL12505752 0.85 CA12 (0.39) CA12CA9HTTALDH1A1MAPT
SCHEMBL31161039 0.84 SMN1; SMN2 (0.36) HTTALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL14916185 0.83 HTT (0.39) HTTALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL320822 0.83 ALDH1A1 (0.37) HTTALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL320577 0.82 MAPT (0.34) HTTALDH1A1MAPTLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590975-B1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-08-19 EP disclosed
US-8859544-B2 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI (FR) 2014-10-14 US disclosed
EP-2590975-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-15 EP disclosed
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 US disclosed
WO-2012004731-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, INMT, IDO1 CA12 4471/4885CA9 3240/4885FEN1 3587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.